A phase 1 trial of zelenectide pevedotin in breast cancer patients
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Zelenectide pevedotin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms Duravelo-3
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to a Bicycle Therapeutics media release, company to initiate this trial in 1H 2025.